[
    {
        "title": "<a href=\"/regulatory-information/search-fda-guidance-documents/evaluation-sex-differences-clinical-investigations\">Evaluation of Sex Differences in Clinical Investigations:  Guidance for Industry</a>",
        "field_associated_media_2": "<a href=\"/media/185362/download\">PDF (209.31 KB)<span class=\"sr-only\">PDF (209.31 KB) of Evaluation of Sex Differences in Clinical Investigations:  Guidance for Industry</span></a>",
        "field_issue_datetime": "01/20/2025",
        "field_issuing_office_taxonomy": "Office of the Commissioner,Office of the Chief Medical Officer,Office of Clinical Policy",
        "field_health_topics": "",
        "term_node_tid": "Good Clinical Practice (GCP)",
        "field_topics": "",
        "topics-product": "Good Clinical Practice (GCP)",
        "field_final_guidance_1": "Final",
        "open-comment": "  No ",
        "field_comment_close_date": "",
        "field_docket_number": "<a href=\"https://www.regulations.gov/docket/FDA-2013-S-0610 \">FDA-2013-S-0610 </a>",
        "field_communication_type": "Information Sheet",
        "field_center": "Office of the Commissioner",
        "field_regulated_product_field": "Biologics, Drugs",
        "changed": "<time datetime=\"2025-02-05T08:51:09-05:00\">2025-02-05 08:51</time>\n",
        "pdf": "evaluation_of_sex_differences_in_clinical_investigations_january_2025.pdf",
        "clean_title": "Evaluation of Sex Differences in Clinical Investigations"
    },
    {
        "title": "<a href=\"/regulatory-information/search-fda-guidance-documents/obesity-and-overweight-developing-drugs-and-biological-products-weight-reduction\">Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction</a>",
        "field_associated_media_2": "<a href=\"/media/71252/download\">PDF (412.63 KB)<span class=\"sr-only\">PDF (412.63 KB) of Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction</span></a>",
        "field_issue_datetime": "01/07/2025",
        "field_issuing_office_taxonomy": "Center for Drug Evaluation and Research",
        "field_health_topics": "",
        "term_node_tid": "Clinical - Medical",
        "field_topics": "",
        "topics-product": "Clinical - Medical",
        "field_final_guidance_1": "Draft",
        "open-comment": "  No ",
        "field_comment_close_date": "04/08/2025",
        "field_docket_number": "<a href=\"https://www.regulations.gov/docket/FDA-2007-D-0435\">FDA-2007-D-0435</a>",
        "field_communication_type": "Guidance Document",
        "field_center": "Center for Drug Evaluation and Research",
        "field_regulated_product_field": "Drugs",
        "changed": "<time datetime=\"2025-01-08T14:32:18-05:00\">2025-01-08 14:32</time>\n",
        "pdf": "Developing-Products-for-Weight-Management-Revision-1.pdf",
        "clean_title": "Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction"
    },
    {
        "title": "<a href=\"/regulatory-information/search-fda-guidance-documents/evaluation-sex-specific-data-medical-device-clinical-studies-guidance-industry-and-food-and-drug\">Evaluation of Sex-Specific Data in Medical Device Clinical Studies - Guidance for Industry and Food and Drug Administration Staff</a>",
        "field_associated_media_2": "<a href=\"/media/82005/download\">PDF (817.04 KB)<span class=\"sr-only\">PDF (817.04 KB) of Evaluation of Sex-Specific Data in Medical Device Clinical Studies - Guidance for Industry and Food and Drug Administration Staff</span></a>",
        "field_issue_datetime": "03/31/2025",
        "field_issuing_office_taxonomy": "Center for Devices and Radiological Health",
        "field_health_topics": "",
        "term_node_tid": "Good Clinical Practice (GCP)",
        "field_topics": "Premarket",
        "topics-product": "Premarket, Good Clinical Practice (GCP)",
        "field_final_guidance_1": "Final",
        "open-comment": "  No ",
        "field_comment_close_date": "",
        "field_docket_number": "<a href=\"https://www.regulations.gov/docket/FDA-2011-D-0817\">FDA-2011-D-0817</a>",
        "field_communication_type": "Guidance Document",
        "field_center": "Center for Devices and Radiological Health",
        "field_regulated_product_field": "Medical Devices",
        "changed": "<time datetime=\"2025-03-31T14:17:18-04:00\">2025-03-31 14:17</time>\n",
        "pdf": "Evaluation-of-Sex-Specific-Data-in-Medical-Device-Clinical-Studies---Guidance-for-Industry-and-Food-and-Drug-Administration-Staff.pdf",
        "clean_title": "Evaluation of Sex-Specific Data in Medical Device Clinical Studies - Guidance for Industry and Food and Drug Administration Staff"
    },
    {
        "title": "<a href=\"/regulatory-information/search-fda-guidance-documents/cvm-gfi-187b-heritable-intentional-genomic-alterations-animals-approval-process\">CVM GFI #187B Heritable Intentional Genomic Alterations in Animals: The Approval Process</a>",
        "field_associated_media_2": "<a href=\"/media/150658/download\">PDF (820.56 KB)<span class=\"sr-only\">PDF (820.56 KB) of CVM GFI #187B Heritable Intentional Genomic Alterations in Animals: The Approval Process</span></a>",
        "field_issue_datetime": "01/07/2025",
        "field_issuing_office_taxonomy": "Center for Veterinary Medicine",
        "field_health_topics": "",
        "term_node_tid": "Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)",
        "field_topics": "Premarket, Biotechnology",
        "topics-product": "Premarket, Biotechnology, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)",
        "field_final_guidance_1": "Final",
        "open-comment": "  No ",
        "field_comment_close_date": "07/31/2024",
        "field_docket_number": "<a href=\"https://www.regulations.gov/docket/FDA-2019-D-2648\">FDA-2019-D-2648</a>",
        "field_communication_type": "Guidance Document",
        "field_center": "Center for Veterinary Medicine",
        "field_regulated_product_field": "Animal &amp; Veterinary",
        "changed": "<time datetime=\"2025-01-06T08:54:09-05:00\">2025-01-06 08:54</time>\n",
        "pdf": "GFI187B_0.pdf",
        "clean_title": "CVM GFI #187B Heritable Intentional Genomic Alterations in Animals: The Approval Process"
    },
    {
        "title": "<a href=\"/regulatory-information/search-fda-guidance-documents/pulse-oximeters-medical-purposes-non-clinical-and-clinical-performance-testing-labeling-and\">Pulse Oximeters for Medical Purposes - Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations: Draft Guidance for Industry and  Food and Drug Administration Staff</a>",
        "field_associated_media_2": "<a href=\"/media/184896/download\">PDF (993.27 KB)<span class=\"sr-only\">PDF (993.27 KB) of Pulse Oximeters for Medical Purposes - Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations: Draft Guidance for Industry and  Food and Drug Administration Staff</span></a>",
        "field_issue_datetime": "01/07/2025",
        "field_issuing_office_taxonomy": "Center for Devices and Radiological Health",
        "field_health_topics": "",
        "term_node_tid": "",
        "field_topics": "Premarket",
        "topics-product": "Premarket, ",
        "field_final_guidance_1": "Draft",
        "open-comment": "  No ",
        "field_comment_close_date": "03/10/2025",
        "field_docket_number": "<a href=\"https://www.regulations.gov/docket/FDA-2023-N-4976\">FDA-2023-N-4976</a>",
        "field_communication_type": "Guidance Document",
        "field_center": "Center for Devices and Radiological Health",
        "field_regulated_product_field": "Medical Devices",
        "changed": "<time datetime=\"2025-01-13T12:27:04-05:00\">2025-01-13 12:27</time>\n",
        "pdf": "pulse-oximeters-for-medical-purposes-draft-guidance_0.pdf",
        "clean_title": "Pulse Oximeters for Medical Purposes - Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations"
    },
    {
        "title": "<a href=\"/regulatory-information/search-fda-guidance-documents/recommendations-reduce-risk-transmission-disease-agents-associated-sepsis-human-cells-tissues-and\">Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Draft Guidance for Industry</a>",
        "field_associated_media_2": "<a href=\"/media/186261/download\">PDF (273.87 KB)<span class=\"sr-only\">PDF (273.87 KB) of Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Draft Guidance for Industry</span></a>",
        "field_issue_datetime": "05/02/2025",
        "field_issuing_office_taxonomy": "Center for Biologics Evaluation and Research",
        "field_health_topics": "",
        "term_node_tid": "Tissue",
        "field_topics": "",
        "topics-product": "Tissue",
        "field_final_guidance_1": "Draft",
        "open-comment": "  Yes  ",
        "field_comment_close_date": "07/07/2025",
        "field_docket_number": "<a href=\"https://www.regulations.gov/docket/FDA-2024-D-3067\">FDA-2024-D-3067</a>",
        "field_communication_type": "Guidance Document",
        "field_center": "Center for Biologics Evaluation and Research",
        "field_regulated_product_field": "Biologics",
        "changed": "<time datetime=\"2025-05-05T07:32:34-04:00\">2025-05-05 07:32</time>\n",
        "pdf": "fda-sepsisandmtbasdraft-sepsisguidance-revisedclean4-28-25.pdf",
        "clean_title": "Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Draft Guidance for Industry"
    },
    {
        "title": "<a href=\"/regulatory-information/search-fda-guidance-documents/recommendations-reduce-risk-transmission-mycobacterium-tuberculosis-mtb-human-cells-tissues-and\">Recommendations to Reduce the Risk of Transmission of Mycobacterium tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Draft Guidance for Industry</a>",
        "field_associated_media_2": "<a href=\"/media/186259/download\">PDF (421.93 KB)<span class=\"sr-only\">PDF (421.93 KB) of Recommendations to Reduce the Risk of Transmission of Mycobacterium tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Draft Guidance for Industry</span></a>",
        "field_issue_datetime": "05/02/2025",
        "field_issuing_office_taxonomy": "Center for Biologics Evaluation and Research",
        "field_health_topics": "Tuberculosis",
        "term_node_tid": "Tissue",
        "field_topics": "",
        "topics-product": "Tuberculosis, Tissue",
        "field_final_guidance_1": "Draft",
        "open-comment": "  Yes  ",
        "field_comment_close_date": "07/07/2025",
        "field_docket_number": "<a href=\"https://www.regulations.gov/docket/FDA-2024-D-3863\">FDA-2024-D-3863</a>",
        "field_communication_type": "Guidance Document",
        "field_center": "Center for Biologics Evaluation and Research",
        "field_regulated_product_field": "Biologics",
        "changed": "<time datetime=\"2025-05-05T07:33:32-04:00\">2025-05-05 07:33</time>\n",
        "pdf": "fda-sepsisandmtbasdrafts-mtbguidance-revisedclean4-28-25.pdf",
        "clean_title": "Recommendations to Reduce the Risk of Transmission of Mycobacterium tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Draft Guidance for Industry"
    },
    {
        "title": "<a href=\"/regulatory-information/search-fda-guidance-documents/recommendations-reduce-risk-transfusion-transmitted-malaria-0\">Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria: Draft Guidance for Industry</a>",
        "field_associated_media_2": "<a href=\"/media/185138/download\">PDF (335.94 KB)<span class=\"sr-only\">PDF (335.94 KB) of Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria: Draft Guidance for Industry</span></a>",
        "field_issue_datetime": "01/15/2025",
        "field_issuing_office_taxonomy": "Center for Biologics Evaluation and Research",
        "field_health_topics": "Blood",
        "term_node_tid": "Blood Products",
        "field_topics": "",
        "topics-product": "Blood, Blood Products",
        "field_final_guidance_1": "Draft",
        "open-comment": "  No ",
        "field_comment_close_date": "",
        "field_docket_number": "<a href=\"https://www.regulations.gov/docket/FDA-2000-D-0187\">FDA-2000-D-0187</a>",
        "field_communication_type": "Guidance Document",
        "field_center": "Center for Biologics Evaluation and Research",
        "field_regulated_product_field": "Biologics",
        "changed": "<time datetime=\"2025-01-17T09:01:32-05:00\">2025-01-17 09:01</time>\n",
        "pdf": "recommendations-to-reduce-risk-of-transfusion-transmitted-malaria_january-2025.pdf",
        "clean_title": "Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria: Draft Guidance for Industry"
    },
    {
        "title": "<a href=\"/regulatory-information/search-fda-guidance-documents/prevention-and-treatment-chemotherapy-induced-peripheral-neuropathy-developing-drug-and-biological\">Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology</a>",
        "field_associated_media_2": "<a href=\"/media/185154/download\">PDF (246.3 KB)<span class=\"sr-only\">PDF (246.3 KB) of Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology</span></a>",
        "field_issue_datetime": "01/17/2025",
        "field_issuing_office_taxonomy": "Oncology Center of Excellence",
        "field_health_topics": "",
        "term_node_tid": "",
        "field_topics": "",
        "topics-product": "",
        "field_final_guidance_1": "Draft",
        "open-comment": "  No ",
        "field_comment_close_date": "03/18/2025",
        "field_docket_number": "<a href=\"https://www.regulations.gov/docket/FDA-2024-D-5663 \">FDA-2024-D-5663 </a>",
        "field_communication_type": "Guidance Document",
        "field_center": "Office of the Commissioner",
        "field_regulated_product_field": "Biologics, Drugs",
        "changed": "<time datetime=\"2025-01-16T14:12:06-05:00\">2025-01-16 14:12</time>\n",
        "pdf": "draft_guidance_cipninoncology_jan_2025_0.pdf",
        "clean_title": "Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology"
    }
]